C0621
CI-994
≥98% (HPLC), HDAC Inhibitor, powder
別名:
4-アセチルアミノ-N-(2′-アミノフェニル)ベンズアミド, アセチルジナリン, タセジナリン
ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
実験式（ヒル表記法）:
C15H15N3O2
CAS番号:
分子量:
269.30
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
製品名
CI-994, ≥98% (HPLC), powder
SMILES string
CC(=O)Nc1ccc(cc1)C(=O)Nc2ccccc2N
InChI key
VAZAPHZUAVEOMC-UHFFFAOYSA-N
InChI
1S/C15H15N3O2/c1-10(19)17-12-8-6-11(7-9-12)15(20)18-14-5-3-2-4-13(14)16/h2-9H,16H2,1H3,(H,17,19)(H,18,20)
assay
≥98% (HPLC)
form
powder
color
off-white
solubility
DMSO: >10 mg/mL
storage temp.
room temp
Quality Level
Gene Information
関連するカテゴリー
Biochem/physiol Actions
CI-994は、化合物Dinaline(PD 104 208)のアセチル化誘導体です。白血病細胞と正常幹細胞に対して顕著な特異的活性を有する経口細胞分裂阻害薬です。非小細胞肺癌、膵臓癌、乳癌、結腸直腸癌を含む特定の腫瘍の併用療法に利用されます。ヒストン脱アセチル化酵素として作用します。CI-994は、細胞周期のG1期からS期の細胞をブロックします。16kDaのリン酸化タンパク質は、核コンパートメントに限定されます。16kDaの核リン酸化タンパク質の消失は、CI-994処理の直接的な影響と考えられるため、このリン酸化タンパク質の阻害がCI-994の作用機序において重要な役割を持つ可能性があります。
Orally available HDAC Inhibitor; CI-994 blocks cells in the G1-S phase of the cell cycle.
Application
CI-994 has been used:
- as an histone deacetylase (HDAC) inhibitor to treat SUM229 and DT22 cells to study its effects
- as an HDAC inhibitor for screening in SPEL cells
- to study its effects on human myeloid and erythroid progenitors
Features and Benefits
This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2
保管分類
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Establishing and characterizing a new primary effusion lymphoma cell line harboring Kaposi?s sarcoma-associated herpesvirus
Osawa M, et al.
Infectious Agents and Cancer, 11(1), 37-37 (2016)
S D Undevia et al.
Annals of oncology : official journal of the European Society for Medical Oncology, 15(11), 1705-1711 (2004-11-03)
This study was conducted to determine the toxicity profile, maximum tolerated dose (MTD) and pharmacokinetics of the putative histone deacetylase inhibitor CI-994 in combination with capecitabine. Fifty-four patients were treated according to three different dosing schemes in which the capecitabine
S Prakash et al.
Investigational new drugs, 19(1), 1-11 (2001-04-09)
CI-994 (N-acetyl dinaline, PD 123654) is a novel oral agent active in a broad variety of murine and human tumor xenografts. While cytotoxic in the Brown Norway (BN) rat leukemia model, growth inhibition in other murine and human tumor xenografts
Suxiang Zhang et al.
Cell death & disease, 9(5), 460-460 (2018-04-28)
Spinal cord injury (SCI) induces severe and long-lasting neurological disability. Accumulating evidence has suggested that histone deacetylase (HDAC) inhibitors exert neuroprotective effects against various insults and deficits in the central nervous system. In the present study, we assessed the effect
The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer.
Cesare Gridelli et al.
Critical reviews in oncology/hematology, 68(1), 29-36 (2008-04-22)
Non-small-cell lung cancer (NSCLC) arises from a complex series of genetic and epigenetic changes leading to uncontrolled cell growth and metastases. The exponential growth in the level of research about the histone deacetylase (HDAC) enzymes, responsible for deacetylating core nucleosomal
資料
We offer a variety of small molecule research tools, such as transcription factor modulators, inhibitors of chromatin modifying enzymes, and agonists/antagonists for target identification and validation in gene regulation research; a selection of these research tools is shown below.
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）